Skip to main content
S&P 5007,585.73-0.45%DOW52,093.11-0.63%NASDAQ25,981.57-0.78%BTC$75,759.00-1.62%ETH$2,400.36-3.30%GOLD$4,385.60+1.22%OIL$104.06-1.67%
Smart Investors Daily
NE

NASDAQ · NERV

Minerva Neurosciences, Inc.

Healthcare · Biotechnology

$3.83

Down-$0.18 (-4.49%)

Updated Sep 16, 2026, 12:43 PM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
28.95M
P/E ratio
2.79
Dividend yield
0.00%
52-week range
$1.93 – $12.46
Volume
287.17K
Avg. volume
3.01M

Price performance

NERV price history

1M range · 20 trading sessions · Daily adjusted prices

NERV closed at $3.83 after 20 trading sessions, down 15.64% for the selected period.

Last close
$3.83
Period change
-15.64%
Period low
$3.83
Period high
$5.43
Daily close
View OHLC price history
NERV OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$4.01$4.05$3.57$3.83287.17K
Sep 14, 2026$4.30$4.385$3.98$4.01119.44K
Sep 11, 2026$4.24$4.375$4.13$4.15135.95K
Sep 10, 2026$4.10$4.235$4.10$4.1672.1K
Sep 9, 2026$4.35$4.4277$4.10$4.12112.06K
Sep 8, 2026$4.40$4.4585$4.32$4.3791.83K
Sep 4, 2026$4.66$4.80$4.42$4.4378.44K
Sep 3, 2026$4.53$4.725$4.39$4.69151.22K
Sep 2, 2026$4.50$4.60$4.46$4.4882.83K
Sep 1, 2026$4.53$4.64$4.46$4.4890.77K
Aug 31, 2026$4.82$4.885$4.52$4.56116.33K
Aug 28, 2026$5.17$5.30$4.82$4.84136.73K
Aug 27, 2026$5.43$5.43$5.03$5.1390K
Aug 26, 2026$5.01$5.63$4.98$5.43383.96K
Aug 25, 2026$4.85$5.195$4.705$5.00114.41K
Aug 24, 2026$4.79$4.9428$4.635$4.81111.85K
Aug 21, 2026$4.79$5.07$4.79$4.84106.45K
Aug 20, 2026$4.76$4.88$4.64$4.79133.14K
Aug 19, 2026$4.62$4.96$4.60$4.792.28M
Aug 18, 2026$4.42$4.56$4.3445$4.54100.76K

Latest NERV news

The latest Smart Investors Daily articles mentioning NERV.

Stock researchCompany · Overview

NERV research

Overview

Company profile and research snapshot.

Company profile

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$5.00
Implied upside
—
Analysts
—
NERV recent ratings
DateFirmRatingTarget
Aug 14, 2026JefferiesBuy—
Apr 15, 2026CitizensMarket Outperform—
Mar 12, 2026HC Wainwright & Co.Neutral—
Nov 6, 2025HC Wainwright & Co.Neutral—
Feb 26, 2025HC Wainwright & Co.Neutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 28, 2026

Minerva Neurosciences to Participate in Two Upcoming Investor Conferences

BURLINGTON, Mass., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that management will participate in two upcoming investor conferences. Wells Fargo Healthcare ConferenceDate: Tuesday, September 8Format: 1x1 meetingsLocation: New York, NY 2026 Cantor Global Healthcare ConferenceDate: Wednesday, September 9Format: Fireside cha

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By